Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, 951-8510, Japan.
Human Genetics Laboratory, National Institute of Genetics, Mishima, 411-8540, Japan.
Sci Rep. 2019 Nov 28;9(1):17808. doi: 10.1038/s41598-019-54116-y.
We explored the frequency of germline and somatic mutations in homologous recombination (HR)-associated genes in major histological types of ovarian cancer. We performed targeted sequencing to assess germline and somatic mutations of 16 HR-associated genes and 4 mismatch repair (MMR) genes among 207 ovarian cancer patients (50 high-grade serous carcinomas (HGSC), 99 clear cell carcinomas (CCC), 39 endometrioid carcinomas (EC), 13 mucinous carcinomas (MC), and 6 low-grade serous carcinomas (LGSC)). Germline or somatic mutations of HR-associated genes were detected in 44% of HGSC, 28% of CCC, 23% of EC, 16% of MC, and 17% of LGSC patients. The profile of HR-associated gene mutations was remarkably different among each histological type. Germline BRCA1/2 mutations were frequently detected in HGSC and were rarely observed in CCC, EC, and MC patients. ATM somatic mutation was more frequently detected in CCC (9%) and EC patients (18%) than in HGSC patients (4%). There was a positive correlation between MMR gene mutations and HR-associated gene mutations (p = 0.0072). Our findings might be useful in selection of ovarian cancer patients that should be treated with PARP inhibitors.
我们探讨了同源重组(HR)相关基因种系和体细胞突变在卵巢癌主要组织学类型中的频率。我们对 207 名卵巢癌患者(50 例高级别浆液性癌(HGSC)、99 例透明细胞癌(CCC)、39 例子宫内膜样癌(EC)、13 例黏液性癌(MC)和 6 例低级别浆液性癌(LGSC))的 16 个 HR 相关基因和 4 个错配修复(MMR)基因进行了靶向测序,以评估种系和体细胞突变。在 44%的 HGSC、28%的 CCC、23%的 EC、16%的 MC 和 17%的 LGSC 患者中检测到 HR 相关基因的种系或体细胞突变。HR 相关基因突变的模式在每种组织学类型之间存在显著差异。BRCA1/2 种系突变在 HGSC 中频繁检测到,而在 CCC、EC 和 MC 患者中很少观察到。ATM 体细胞突变在 CCC(9%)和 EC 患者(18%)中比在 HGSC 患者(4%)中更频繁检测到。MMR 基因突变与 HR 相关基因突变之间存在正相关(p=0.0072)。我们的研究结果可能有助于选择应接受 PARP 抑制剂治疗的卵巢癌患者。